We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Novel Saliva Collection Device Keeps Analytes Stable at Ambient Temperatures for Weeks

By LabMedica International staff writers
Posted on 27 Feb 2023

Blood-based diagnostics have been the norm since a long time. More...

However, in the new era of healthcare, providers have adopted salivary collection and preservation to detect viral infections. The process of collecting saliva can make a huge diagnostic difference. Selecting the wrong saliva collection device can create and increase critical failure points. In order to incorporate the use of saliva into molecular diagnostic testing protocols or implement actual real-world mass-testing in scalable scenarios, there is a need for a studied, proven, validated, and supported system that eliminates the risk of exposure and a device that can enhance test precision, sensitivity, and assay reproducibility. Now, a novel saliva collection device is setting new standards of care in testing, managing, and treating diseases.

The SDNA Saliva Collection Device from Spectrum Solutions (Salt Lake City, UT, USA) has the ability to maximize detection at the lowest levels and neutralize viruses within 10-seconds of collection to mitigate unnecessary viral exposure. The company’s patented preservation media keeps analytes stable for several weeks at ambient temperatures, ensuring safe, easy, and secure specimen storage and transport. The SDNA kits do not have any special storage or transport temperature-control requirements for collected saliva samples and eliminate the need for UN3373 biohazard shipping designation. The U.S. Food and Drug Administration (FDA) has granted 510(k) Class II clearance to the SDNA saliva collection device as a microbial nucleic acid storage and stabilization device.

“This 510(k) clearance and certification as an IVD molecular diagnostic device enables physicians, hospitals, researchers and others to leverage our SDNA Saliva Collection Device in a broad array of FDA approved and LDT diagnostic testing applications,” said Stephen Fanning, CEO at Spectrum Solutions. “Those conducting screening and diagnostic tests can confidently and safely expand access and opportunity incorporating saliva as a primary or alternative biomaterial into their existing testing protocols.

Related Links:
Spectrum Solutions


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.